ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date
  • Abstract Number: 2037

    Proteostasis Dysregulation and Autoinflammation in Patients with TRNT1 Deficiency
  • Abstract Number: 2038

    Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis
  • Abstract Number: 2039

    Assessing Barriers to Uveitis Screening in Patients with JIA: A Qualitative Study
  • Abstract Number: 2040

    Responsiveness of Patient Reported Outcomes Measurement Information System Measures in RA Patients Starting or Switching a DMARD
  • Abstract Number: 2041

    Validity and Reliability of Patient Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form in Patients with SLE
  • Abstract Number: 2042

    Improving the Overall Pneumococcal Vaccination Rate in Lupus Patients at the Rheumatology Clinic
  • Abstract Number: 2043

    Feasibility and Accuracy of Translating a Patient Safety Quality Measure into an Automated e-Measure
  • Abstract Number: 2044

    Effect of Pregnancy on Disease Flares in Patients with Systemic Lupus Erythematosus
  • Abstract Number: 2045

    Early Preeclampsia Risk in Lupus Pregnancy: A Swedish Population-Based Register Investigation
  • Abstract Number: 2046

    The Low-Dose Intravenous Cyclophosphamide Euro-Lupus Regimen Does Not Impact the Ovarian Reserve of Lupus Patients, As Measured By Serum Anti-Mullerian Hormone Levels
  • Abstract Number: 2047

    Impact of in Utero Hydroxychloroquine Exposure on the Risk of Cutaneous Neonatal Lupus Erythematosus
  • Abstract Number: 2048

    Evaluating Transfer of Certolizumab Pegol into Breast Milk: Results from a Prospective, Postmarketing, Multicenter Pharmacokinetic Study
  • Abstract Number: 2049

    Serious Infections in RA Offspring Exposed to Tumor Necrosis Factor Inhibitors
  • Abstract Number: 2050

    Screening for and Management of Comorbidities after a Nurse-Led Program: Results of a 3 Year Longitudinal Study in 776 Established RA Patients
  • Abstract Number: 2051

    Risk Factors for Cardiovascular Disease Predate the Onset of Symptoms of Rheumatoid Arthritis
  • « Previous Page
  • 1
  • …
  • 136
  • 137
  • 138
  • 139
  • 140
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology